Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
Tao Jiang(Tongji University), Caicun Zhou(Tongji University)
Cited by 107
Related Papers
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
|Annals of Oncology|2018|217
Early detection of lung cancer by using an autoantibody panel in Chinese population
|OncoImmunology|2017|203
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
|Signal Transduction and Targeted Therapy|2021|94